

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BOREA ET AL.

Group Art Unit: 1614

Serial No.: 10/603,406

Examiner: Gembah, Shirley V.

Filed: June 24, 2003

Attorney Docket No.: PAT-0040-US-NP2

For: ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A₃
ANTAGONISTS

Mail Stop: Amendment

Conf. No.: 4184

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In connection with the above identified Application No. 10/603,406, filed June 24, 2003, Applicants wish to call the Examiner's attention to U.S. Patent No. 6,921,825 to Baraldi et al, and the enclosed journal articles by Baraldi et al. entitled "Pyrozolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A₃ Adenosine Receptor Antagonists: Influence of the Chain at the N⁸ Pyrazole Nitrogen" (*Journal of Medicinal Chemistry* 2000, 43, 4768-4780); and "Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrozolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A₃ Adenosine Receptor Antagonists" (*Journal of Medicinal Chemistry* 2002, 45, 770-780).

It is estimated that no fees are required for filing this Paper. Notwithstanding, should the Commissioner determine otherwise, please charge any necessary fees to Deposit Account No. 50-3706 in the name of King Pharmaceuticals, Inc.

Respectfully submitted,



Paivi Kukkola
(Reg. No. 50,499)

King Pharmaceuticals, Inc.

400 Crossing Boulevard

Bridgewater, NJ 08807

Tel: (908) 429-6000 ext 58964

Encl.: Form 1449/PTO

Date: November 15, 2007